Drug Search Results
More Filters [+]

Fedovapagon

Alternative Names: fedovapagon, va-106483, va106483, va 106483
Latest Update: 2018-10-31
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: V2 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vantia
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fedovapagon

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Nocturia|Prostatic Hyperplasia

Phase 2: Nocturia

Phase 1: Prostatic Hyperplasia|Nocturia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EQUINOC

P3

Completed

Prostatic Hyperplasia|Nocturia

2017-07-01

NCT02537288

P1

Completed

Nocturia

2015-12-01

NCT02440841

P1

Completed

Nocturia

2015-07-01

NCT01656239

P2

Completed

Nocturia

2013-08-01

Recent News Events

Date

Type

Title